Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Candel Therapeutics, Inc. (CADL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Candel is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market under the symbol CADL, as noted in multiple Form 8-K filings. Its filings document material events related to its multimodal viral immunotherapy programs, capital structure, and key agreements.
Investors can review current reports on Form 8-K describing clinical and corporate milestones, such as interim data from the phase 1b trial of CAN-3110 in recurrent glioblastoma, progress with CAN-2409 in localized prostate cancer, NSCLC, and PDAC, and strategic decisions to prioritize certain indications. Other 8-K filings outline financing arrangements, including a Loan and Security Agreement with Trinity Capital Inc. for up to $130 million in term loans, registered direct equity offerings under an effective shelf registration statement, warrant amendments, and lease extensions for facilities in Needham, Massachusetts.
These filings also identify when Candel issues press releases on quarterly financial results, R&D events, and material agreements, and they confirm that CADL common stock is registered under Section 12(b) of the Exchange Act. By examining items such as Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, and Regulation FD Disclosure, users can understand how Candel reports on its financial position, capital resources, and clinical program updates.
On Stock Titan, AI-powered tools can help summarize lengthy Candel filings, highlight key sections, and surface references to topics like CAN-2409, CAN-3110, the enLIGHTEN™ Discovery Platform, and regulatory designations. This allows readers to quickly identify information on term loan covenants, equity offerings, and clinical data disclosures without manually parsing each document.
Candel Therapeutics director Paul B. Manning received a stock option grant covering 4,618 shares of Common Stock. The options have an exercise price of $4.90 per share, were fully vested at the time of grant, and expire on March 31, 2036. According to the filing, this award was given in lieu of normal quarterly cash payments, and following the grant he holds options for 4,618 shares directly.
Candel Therapeutics director Joseph C. Papa received a grant of 2,795 stock options as compensation. The options were awarded on March 31, 2026 with an exercise price of $4.90 per share and relate to 2,795 shares of common stock.
This award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following this grant, Papa holds 2,795 derivative securities directly, and the options are scheduled to expire on March 31, 2036.
Candel Therapeutics director Nicoletta Loggia received a fully vested stock option award covering 779 shares of common stock. The option has an exercise price of $4.90 per share and was granted in lieu of normal quarterly cash payments, leaving her with 779 derivative securities following the grant.
Paul B. Manning and affiliated entities filed an amended Schedule 13D reporting beneficial ownership of 5,790,999 shares of Candel Therapeutics common stock, equal to 7.9% of the outstanding shares. The holdings are spread across Paul and Diane Manning jointly, The Paul B. Manning Revocable Trust, BKB Growth Investments, LLC, and stock options.
As of the filing, Paul and Diane Manning jointly hold 1,681,000 shares, the Trust holds 2,763,527 shares, BKB holds 1,303,752 shares, and 42,720 shares are issuable upon option exercise within 60 days of February 26, 2026. The ownership percentages are based on 73,244,473 shares outstanding as of February 20, 2026.
The amendment also records that on February 23, 2026, the Trust purchased 550,458 shares in an underwritten offering at $5.45 per share for $3 million, adding to earlier investments made through preferred financing, the IPO, open-market purchases, and prior offerings.
Candel Therapeutics, Inc. reports its annual update as a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for solid tumors. Its lead adenoviral candidate, aglatimagene besadenovec, showed a statistically significant disease-free survival benefit in a 745‑patient phase 3 trial in intermediate‑ and high‑risk localized prostate cancer (hazard ratio 0.70; p=0.0155), received RMAT and Fast Track designations, and is being prepared for a planned Biologics License Application submission in the fourth quarter of 2026.
The company is also advancing aglatimagene in non-small cell lung cancer, where a phase 2a trial in patients progressing on checkpoint inhibitors reported median overall survival up to 25.4 months in non-squamous disease versus 9.8–11.8 months in published chemotherapy data. A pancreatic cancer study showed prolonged survival but further work is paused pending external funding. Candel’s HSV-based candidate, linoserpaturev, has produced encouraging survival and immune-activation signals in recurrent high‑grade glioma, supported by Fast Track and Orphan Drug designations, with multiple-dose data and enabling work for a future randomized phase 2 underway. The company also highlights its enLIGHTEN™ Discovery Platform for next‑generation viral immunotherapies, while noting it has no product revenue, expects continuing losses, relies on external manufacturing, and must raise substantial additional capital.
Candel Therapeutics reported fourth quarter and full year 2025 results and outlined key clinical and financing milestones. Research and development expenses rose to $30.5M in 2025 from $19.3M in 2024, while general and administrative expenses increased to $17.8M from $14.1M. Net loss narrowed to $38.2M in 2025 from $55.2M in 2024, helped by $10.1M of net other income, mainly from warrant liability revaluation. Cash and cash equivalents were $119.7M as of December 31, 2025, compared with $102.7M a year earlier.
The company completed a February 2026 follow-on equity offering that generated $93.5M in net proceeds and entered a $130M term loan facility, drawing $50M at closing. Based on these resources, Candel expects to fund its operating plan into Q1 2028. The plan includes a planned pivotal phase 3 trial of aglatimagene besadenovec in non-small cell lung cancer, a planned BLA submission for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026, and continued development of linoserpaturev in recurrent high-grade glioma.
Candel Therapeutics director Paul B. Manning, through The Paul B. Manning Revocable Trust, completed an open-market purchase of 550,458 shares of common stock at $5.45 per share. After this transaction, indirect holdings include shares in the Trust and in BKB Growth Investments, LLC, plus additional shares held directly and jointly with his spouse.
Candel Therapeutics entered into an underwriting agreement for a public stock offering of 18,348,624 common shares at $5.45 per share, for expected gross proceeds of $100 million. Underwriters also have a 30‑day option to buy up to 2,752,293 additional shares.
Candel estimates net proceeds of about $93.5 million, or $107.6 million if the option is fully exercised. The company plans to use the cash to prepare for the launch and commercialization of CAN‑2409 in early localized prostate cancer, continue the phase 3 trial of CAN‑2409 in non‑small cell lung cancer, and for general corporate purposes. Based on the expected proceeds from the base deal, Candel believes its cash and cash equivalents will fund operations into the first quarter of 2028.
Candel Therapeutics is offering 18,348,624 shares of common stock in a primary offering at a public offering price of $5.45 per share, with underwriters granted a 30-day option to purchase up to an additional 2,752,293 shares. The offering’s gross proceeds at the public offering price are shown as $100,000,000.80, with underwriting discounts of $6,000,000.05 and estimated proceeds to the company before expenses of $94,000,000.75.
The prospectus supplement discloses a related Purchase Agreement with funds managed by RTW Investments, LP under which the company would receive $100,000,000 upon FDA marketing approval of CAN-2409 for localized prostate cancer in exchange for a tiered U.S. royalty that begins at 4.67% (with a lower 1.33% tier above $1 billion in annual net sales and a capped Purchaser recovery of $250,000,000). Shares outstanding were 54,895,849 as of September 30, 2025.
Candel Therapeutics is offering $100,000,000 of its common stock. The preliminary prospectus supplement dated February 19, 2026 states the company is offering $100 million of common stock, with an underwriter option to purchase up to an additional $15 million of shares within 30 days.
The cover states the offering is of shares of common stock listed on the Nasdaq Global Market under the symbol CADL. The prospectus supplement references preliminary cash of approximately $119.7 million as of December 31, 2025 and discusses a separate Purchase Agreement providing for a conditional $100 million payment from funds managed by RTW Investments, LP upon FDA marketing approval of CAN-2409, in exchange for tiered U.S. royalties.
Candel Therapeutics is offering $100,000,000 of its common stock. The preliminary prospectus supplement dated February 19, 2026 states the company is offering $100 million of common stock, with an underwriter option to purchase up to an additional $15 million of shares within 30 days.
The cover states the offering is of shares of common stock listed on the Nasdaq Global Market under the symbol CADL. The prospectus supplement references preliminary cash of approximately $119.7 million as of December 31, 2025 and discusses a separate Purchase Agreement providing for a conditional $100 million payment from funds managed by RTW Investments, LP upon FDA marketing approval of CAN-2409, in exchange for tiered U.S. royalties.
Candel Therapeutics is offering $100,000,000 of its common stock. The preliminary prospectus supplement dated February 19, 2026 states the company is offering $100 million of common stock, with an underwriter option to purchase up to an additional $15 million of shares within 30 days.
The cover states the offering is of shares of common stock listed on the Nasdaq Global Market under the symbol CADL. The prospectus supplement references preliminary cash of approximately $119.7 million as of December 31, 2025 and discusses a separate Purchase Agreement providing for a conditional $100 million payment from funds managed by RTW Investments, LP upon FDA marketing approval of CAN-2409, in exchange for tiered U.S. royalties.